The slanging match between Netherlands-incorporated Mylan (Nasdaq: MYL) and US drugmaker Perrigo (NYSE: PRGO) has intensified ahead of the Mylan’s shareholder vote on the hostile takeover bid.
On Tuesday, Mylan reported the Irish regulators have found Perrigo making statements that could mislead shareholders and the market or may create uncertainty. Mylan said the statements violated Irish takeover rules.
Mylan executive chairman Robert Coury, said: “Perrigo continues to make misleading comments with regard to Mylan’s offer to acquire Perrigo — comments which unfortunately have been inaccurately repeated by other third parties.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze